MedTrace Logo

Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

NCT01854996 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-06-25

No results posted yet for this study

Summary

This study aims to test plasma exposure to PF-05089771 with same formulation will be used for phase II trials (capsule).

Conditions

  • Healthy

Interventions

DRUG

PF-05089771

450mg

DRUG

PF-05089771

450mg

DRUG

PF-05089771

450mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854996 on ClinicalTrials.gov